https://doi.org/10.5812/ijcm-147330

Adult Uterine Wilm’s Tumor Miss-interpreted as Carcinosarcoma: A Case Report

authors:

avatar Narges Izadi-Mood 1 , * , avatar Fatemeh Nili ORCID 1 , avatar Soheila Sarmadi ORCID 1 , avatar Elham Mirzaian 1

Tehran University of Medical Sciences, Tehran, Iran
International Journal of Cancer Management: Vol.17, issue 1; e147330
published online: September 18, 2024
article type: Case Report
received: April 14, 2024
revised: August 2, 2024
accepted: August 14, 2024

How To Cite Izadi-Mood N, Nili F, Sarmadi S, Mirzaian E. Adult Uterine Wilm’s Tumor Miss-interpreted as Carcinosarcoma: A Case Report. Int J Cancer Manag. 2024;17(1):e147330. https://doi.org/10.5812/ijcm-147330.

Abstract

Introduction:

Wilm’s tumor (WT) is a common renal malignancy in children. Adult extrarenal WT involving the uterus is extremely rare. Herein, we reported a case of uterine WT in an old woman who was primarily diagnosed with carcinosarcoma.

Case Presentation:

A 63-year-old woman presented with abdominal pain and radiologic evidence of pelvic mass originating from the uterus, which was suggestive of sarcoma. Her Serum levels of Cancer Antigen 125 (CA125), Human Epididymis protein 4 (HE4), Cancer Antigen 19-9 (CA19-9), and Alpha Fetoprotein (AFP) were found to be elevated. She underwent total hysterectomy, bilateral salpingo-oophrectomy, and omentectomy. Pathologic examination of the specimens revealed a large uterine mass with serosal surface and omental invasion. The initial diagnosis was carcinosarcoma based on the mixed epithelial and mesenchymal components observed on microscopic examination. Triphasic components of papillary, primitive tubules, and glomeruloid structures, along with mesenchymal and blastemal elements were identified upon second opinion. An immunohistochemistry (IHC) study revealed positive reactions for WT1, CKAE1 /AE3, EMA, Glypican-3, and CD56 in all components of the tumor cells. P53 expression was normal. GATA3, ER, PR, and CD10 were negative. The final diagnosis was changed to WT.

Conclusions:

Uterine WT is an extremely rare malignancy, which could be associated with elevated serum AFP. Diagnosis and treatment of these rare tumors pose challenges for both pathologists and clinicians.

1. Introduction

Wilms tumor (WT) or nephroblastoma is one of the most common childhood malignancies, which primarily involves renal tissue (1). The tumor originates from nephrogenic blastoma and imitates the histology of developing kidneys (2). Extrarenal WT is rare and occurs in 0.5 to 1% of WTs, mostly in children (3, 4). The most common extrarenal locations of WT include the retroperitoneum, inguinal area, lumbosacral and pelvic cavity, mediastinum, chest wall, spermatic cord/paratesticular region, and female genital organs (3).

Microscopically, classic WT is composed of three components such as blastemal, mesenchymal, and epithelial. Blastemal component consists of small to medium-sized undifferentiated cells with high mitotic activity. Epithelial components may consist of well-differentiated glandular, tubular or glomerular structures or poorly differentiated rosette-like structures. The stromal component includes spindle cells with or without heterologous elements (5).

Carcinosarcoma or malignant mixed mullerian tumor is a rare biphasic aggressive tumor of the uterine corpus. Carcinosarcoma mostly occurs in post-menopausal women. Microscopically, the tumor is composed of high-grade epithelial carcinoma and high-grade sarcoma. The sarcomatous component is derived from carcinoma cells as a result of epithelial-mesenchymal trans-differentiation. Heterologous rhabdomyosarcoma, chondrosarcoma or osteosarcoma components may also be present (6).

Herein, we reported a 63-year-old woman with advanced staged uterine cancer with epithelial and stromal components which was primarily misdiagnosed as carcinosarcoma. After the review of the slides by expert Gynecopathologists, the diagnosis was changed to uterine WT. Adult uterine WT is extremely rare with only 10 reported cases in English Literature.

Alpha fetoprotein (AFP) is an oncofetal protein of typically hepatoid and germ cell tumors, especially yolk sac tumor (7). Increased serum level of AFP in WT is not usual. There are few reported cases in this regard (7-10). Elevated serum AFP is the other interesting aspect of this case report.

2. Case Presentation

A 63-year-old menopausal woman, G5 L4 D1 presented with continuous mild lower abdominal pain for one month before her admission to the hospital. She had diabetes mellitus, hypertension, and hyperlipidemia and was under medical treatment. Her sister has been treated for thyroid cancer. On physical examination, vital signs were stable and uterus was larger than normal size. No other abnormal finding was detected. Abdominal and pelvic sonography and MRI showed 19 × 10 × 9 cm pelvic mass with uterine origin, suggestive of sarcoma. The cervix and adnexae were free from the tumor. Upper GI endoscopy, colonoscopy, and lung CT scan were normal. No primary liver mass or metastasis was identified. Evaluation of serum tumor markers revealed LDH: 784 IU/mL, CA 19-9: 503 IU/mL, CA 125: 302 IU/mL, ROMA: 94 IU/mL, AFP: 30 IU/mL. A biopsy of the uterine mass revealed necrotic material and a spindle tumor suggestive of sarcoma.

The patient underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. On macroscopic examination, the uterus was large measuring 15 × 11 × 10 cm and deformed. Endometrial cavity was irregular containing tan-yellowish fragile projections that filled the entire endometrial cavity and extended to the myometrium. The serosal surface was ruptured and involved by a tumor. The cervix, ovaries, and fallopian tubes were unremarkable. An omental mass measuring 3.5 cm in greatest dimension was also seen. According to the presence of mixed epithelial-mesenchymal structures and pathologic diagnosis of carcinosarcoma (pathologic stage IV), adjuvant chemotherapy with carboplatin, paclitaxel regimen, and external beam radiotherapy were prescribed. In 6 months follow up after treatment, no residual tumor was detected on imaging studies. Three months after the end of treatment, the patient presented with sub-hepatic recurrent mass and abdominal lymphadenopathies.

On review of pathology slides in another center (Yas Women's Hospital), a microscopic examination showed a triphasic tumor composed of epithelial, mesenchymal, and blastemal components. The epithelial component consisted of papillary structures, primitive tubules, and glomeruloid structures compatible with WT. Heterologous rhabdomyoblastic differentiation was also seen in the mesenchymal component (Figures 1 and 2). A complementary immunohistochemical (IHC) study showed a positive reaction for WT1, CKAE1 /AE3, EMA, Glypican-3, desmin, and CD56 in all components of the tumor, while P53 expression was normal. Tumor was negative in staining for GATA3, ER, PR, and CD10 (Figure 3A – H and Table 1). The patient received a second line of chemotherapy for WT. Unfortunately, she died 3 months after initiation of the treatment.

Microscopic examination of hematoxilin and eosin-stained sections shows; A, infiltration of myometrial tissue with a triphassic tumor composed of epithelial, blastemal, and mesenchymal structures (40X); B, glomeruloid structures and primitive tubules surrounded by spindle cells (100X); C, epithelial cells of the tubular structures and spindle cells showing mild nuclear atypia at high power examination (400X).
Microscopic examination of hematoxilin and eosin-stained sections shows; A, infiltration of myometrial tissue with a triphassic tumor composed of epithelial, blastemal, and mesenchymal structures (40X); B, glomeruloid structures and primitive tubules surrounded by spindle cells (100X); C, epithelial cells of the tubular structures and spindle cells showing mild nuclear atypia at high power examination (400X).
Figure 1.

Microscopic examination of hematoxilin and eosin-stained sections shows; A, infiltration of myometrial tissue with a triphassic tumor composed of epithelial, blastemal, and mesenchymal structures (40X); B, glomeruloid structures and primitive tubules surrounded by spindle cells (100X); C, epithelial cells of the tubular structures and spindle cells showing mild nuclear atypia at high power examination (400X).

A, On low-power examination, leaf-like appearance and peri glandular cuffing mimic mullerian adenosarcoma (40X); B, Papillary structures are short, small, and non-branching, lined by epithelial cells with minimal atypia (100X); C, Heterologous rhabdomyoblastic differentiation in the mesenchymal component is seen (400X).
A, On low-power examination, leaf-like appearance and peri glandular cuffing mimic mullerian adenosarcoma (40X); B, Papillary structures are short, small, and non-branching, lined by epithelial cells with minimal atypia (100X); C, Heterologous rhabdomyoblastic differentiation in the mesenchymal component is seen (400X).
Figure 2.

A, On low-power examination, leaf-like appearance and peri glandular cuffing mimic mullerian adenosarcoma (40X); B, Papillary structures are short, small, and non-branching, lined by epithelial cells with minimal atypia (100X); C, Heterologous rhabdomyoblastic differentiation in the mesenchymal component is seen (400X).

Immunohistochemistry study shows positive staining for CKAE1/AE3, CD56, Desmin, and WT1, respectively (A - D); wild-type expression of P53 (E); and negative staining for ER/PR and GATA3 are seen (F, G); Ki67 shows high proliferative activity (H).
Immunohistochemistry study shows positive staining for CKAE1/AE3, CD56, Desmin, and WT1, respectively (A - D); wild-type expression of P53 (E); and negative staining for ER/PR and GATA3 are seen (F, G); Ki67 shows high proliferative activity (H).
Figure 3.

Immunohistochemistry study shows positive staining for CKAE1/AE3, CD56, Desmin, and WT1, respectively (A - D); wild-type expression of P53 (E); and negative staining for ER/PR and GATA3 are seen (F, G); Ki67 shows high proliferative activity (H).

Table 1.

Positive and Negative IHC Markers in Different Components of the Tumor Cells

IHC MarkerReactivity in Tumor Cells of Epithelial ComponentReactivity in Tumor Cells of Mesenchymal ComponentReactivity in Tumor Cells of Blastemal Component
CK AE1/AE3++/-+
EMA++/-+
WT1++/-+
Glypican-3+++
Desmin +/-++/-
CD56+++
P53NormalNormalNormal
GATA3---
ER---
PR---
CD10---

3. Discussion

The first case of extrarenal WT (in the mediastinum) was reported in 1961 by Moyson et al. (3, 11). The first case of uterine WT was reported by Bittencourt et al. in 1981 (12). Till now, only 10 cases of uterine corpus WT have been reported (Table 2) (13-20). Age of the patients ranged between 14 and 77 years. The most common symptom was abnormal uterine bleeding followed by abdominal pain and abdominal mass. About half of the reported cases revealed extrauterine spread at the time of diagnosis. Except for one case, which was inoperable at the time of diagnosis, the others were treated by TAH, BSO surgery, and adjuvant treatment (radiation, chemotherapy, or both). The molecular alteration was evaluated by Alessandrini et al. in the most recent extrarenal WT case (13). Molecular analysis revealed no microsatellite instability and unaltered tumor mutational burden. Copy number variations in the ERBB2, FGFR23, FGF6, FGFR2, and RPS6KB1 genes were reported.

Table 2.

Previously Reported Cases of Uterine WT in English Literature

First Author Year of PublicationAgeClinical PresentationExtrauterine Organ InvolvementTreatmentOutcomeFollow-up Time
Bittencourt (12)198114Abdominal pain and massFallopian tube and posterior vaginaTAH, BSO, radiation, chemotherapyalive5 years
Comerci (16)199322AUBNoTAHalive2 years
Jiskoot (17)199977Polypoid mass, AUBPositive abdominal washing cytologyTAH, BSO, radiationalive4 months
Muc (19)200142AUB, protruded massTransmural uterine extensionTAH, BSO (subtotal), radiationRecurrence; dead6 months later; 1 year after
McAlpine (14)200544AUBParametrium, sacrouterine ligamentTAH, BSO, complete staging, chemotherapyalive1 year
Leblebici (18)200916Abdominal pain, AUB, weight lossChemotherapy (inoperable)diedA few days after chemo
Garsia Galris (15)200962AUBNoTAH, BSO, radiation, chemotherapyalive14 months
Cao et al. (21)201760AUBNoTAH, BSO, chemotherapyalive18 months
Pinto (20)201833AUB, pelvic painNoRadical hysterectomy, BSO, omentectomyNot applicable (NA)NA
Alessandrini (13)202359Abdominal painNoTAH, BSO, omentectomy, appendectomyradiation, chemotherapyalive6 months
Present case202463Abdominal and pelvic painTransmural uterine serosa and omentumTAH, BSO, omentectomy, radiation, chemotherapyRecurrence; Dead3 months

Abbreviation: AUB, Abnormal uterine bleeding.

Several pathogenic theories have been suggested for extrarenal WT (3). Some authors believe that extrarenal WT originates from Teratomas. Although in new classifications teratoid WT is distinguished from pure extrarenal WT. True primary extrarenal WT should lack teratoid elements. The most wildly accepted pathogenic hypothesis is the oncogenic transformation of ectopic nephrogenic rests to develop WT (3).

The diagnosis is based on pathologic features (4). Classic WT is composed of three blastemal, mesenchymal, and epithelial components. Although monophasic or biphasic tumors are not infrequent. The tumor cell nuclei are positive for WT1, in more than 90% and Glypican-3 is positive in the majority of the cases. CK, EMA, CD56 and CD57 are variably positive in epithelial component (5).

Carcinosarcoma is the most important differential diagnosis in uterus WT, especially among old patients. Lack of high nuclear features in both epithelial and stromal components, presence of primitive tubular and glomeruloid structures in epithelial elements, diffuse strong staining for WT1 and Glypican-3 and negative staining for ER/PR, as well as normal expression of p53 on IHC study, are all supportive of the WT diagnosis.

Mesonephric/ Mesonephric-like carcinoma is another differential diagnosis for uterus WT. Mesonephric/ Mesonephric-like carcinoma may show different morphologic patterns including papillary, ductal, solid, and spindle cell structures with mild to moderate nuclear atypia (22). Small tubular structures containing eosinophilic material and characteristic nuclear features resembling papillary thyroid carcinoma, were not identified in our case. GATA3, and TTF1, were also negative in the IHC study. Presence of leaf-like structures, peri-glandular cuffing, and minimal atypia in epithelial and spindle cell component, mimic Mullerian adenosarcoma (Figure 1A). Lack of immune reaction with ER and PR in epithelial cells and the presence of primitive tubular and glomeruloid structures are helpful in excluding this differential diagnosis.

There is no specific serum marker for the diagnosis of WT. Increased serum erythropoietin, Neuron-specific enolase, Carcino-eberyonic antigen, renin, and hormone tumor markers have been reported in WT. Elevated serum AFP is an unusual finding, which has been reported in a few cases of pediatric renal WT (7-10). Teratoid WT is expected to show increased AFP due to the presence of heterologous elements. However, as discussed earlier, Teratoid WT is not classified as primary WT (3, 23). In addition to the yolk sac and hepatic tumors, some other germ cell tumors including teratoma and somatic malignancies of gastrointestinal, lung, and breast could be associated with AFP secretion (24). In epithelial tumors of the female genital tract, increased AFP has been reported in different histologic subtypes with yolk sac or hepatoid differentiation and small cell neuroendocrine carcinoma (25-27). Our case was rigorously investigated with imaging studies and GI consultation to exclude the possibility of hepatic tumors. This is the first case report of extrarenal WT of the uterus with elevated AFP.

There is no consensus about treatment, follow-up, and prognosis of adult and especially uterine WT (28). Most of the previously reported cases and our case underwent hysterectomy. Only one case underwent chemotherapy as the initial treatment, which could not save the patient.

5.1. Conclusions

Uterine Wilm’s tumor is an extremely rare malignancy, which could be associated with elevated serum AFP. Diagnosis and treatment of this rare tumor is challenging for both pathologists and clinicians. Therefore, uterine WT should be considered as a differential diagnosis in malignant uterine tumors to help accurate diagnosis and future treatment planning.

References

  • 1.

    Cunningham ME, Klug TD, Nuchtern JG, Chintagumpala MM, Venkatramani R, Lubega J, et al. Global disparities in Wilms tumor. J Surgical Res. 2020;247:34-51. https://doi.org/10.1016/j.jss.2019.10.044.

  • 2.

    Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. American journal of medical genetics. 1998;79(4):268-73.

  • 3.

    Shojaeian R, Hiradfar M, Sharifabad PS, Zabolinejad N. Extrarenal Wilms' tumor: challenges in diagnosis, embryology, treatment and prognosis. United Nations, Brisbane (AU): Exon Publications; 2016.

  • 4.

    Liang H, He Y, Fu L, Tian J, Sun N, Yu T, et al. Extrarenal Wilms tumor in children: A retrospective observational case series. J Pediatr Urol. 2020;16(5):6640-7. eng. [PubMed ID: 32758416]. https://doi.org/10.1016/j.jpurol.2020.07.016.

  • 5.

    Vujanić GM, Sandstedt B. The pathology of Wilms' tumour (nephroblastoma): the International Society of Paediatric Oncology approach. J Clin Pathol. 2010;63(2):102-9. eng. [PubMed ID: 19687012]. https://doi.org/10.1136/jcp.2009.064600.

  • 6.

    Pezzicoli G, Moscaritolo F, Silvestris E, Silvestris F, Cormio G, Porta C, et al. Uterine carcinosarcoma: An overview. Crit Rev Oncol Hematol. 2021;163:103369. eng. [PubMed ID: 34051304]. https://doi.org/10.1016/j.critrevonc.2021.103369.

  • 7.

    Dhungel S, Cheng LJ, Hai ZZ. Elevated serum alpha-fetoprotein in Wilms' tumor: A case report with review of literature. Journal of Pediatric Surgery Case Reports. 2014;2(3):153-5. https://doi.org/10.1016/j.epsc.2014.02.015.

  • 8.

    Bothra J, Shah H, Tiwari C. Classic Wilms' tumor with raised alpha-fetoprotein levels: A case report and literature review. Pediatric Urology Case Reports. 2017;4(1):238-43. https://doi.org/10.14534/PUCR.2017124184.

  • 9.

    Green R, Ahmed A, Fleming B, Long AM, Behjati S, Trotman J, et al. Wilms Tumor With Raised Serum Alpha-Fetoprotein: Highlighting the Need for Novel Circulating Biomarkers. Pediatr Dev Pathol. 2024;27(3):260-5. eng. [PubMed ID: 38098239]. [PubMed Central ID: PMC11088205]. https://doi.org/10.1177/10935266231213467.

  • 10.

    Kesik V, Ozcan A, Sari E, Guven A, Kismet E, Koseoglu V. Alpha-fetoprotein producing tumor cells in children with Wilms' tumor. Fetal Pediatr Pathol. 2010;29(3):127-32. eng. [PubMed ID: 20450265]. https://doi.org/10.3109/15513811003777284.

  • 11.

    Moyson F, Maurus-Desmarez R, Gompel C. [Mediastinal Wilms' tumor?]. Acta Chir Belg. 1961;Suppl 2:118-28. French. [PubMed ID: 14476767].

  • 12.

    Bittencourt AL, Britto JF, Fonseca Jr LE. Wilms' tumor of the uterus: the first report of the literature. Cancer. 1981;47(10):2496-9. https://doi.org/10.1002/1097-0142(19810515)47:10<2496::AID-CNCR2820471031>3.0.CO;2-V.

  • 13.

    Alessandrini L, Guerriero A, Munari G, Del Forno B, Santoro L, Marchetti M, et al. A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature. Pathologica. 2023;115(6):333-40. [PubMed ID: 38180141]. [PubMed Central ID: PMC10767795]. https://doi.org/10.32074/1591-951x-943.

  • 14.

    McAlpine J, Azodi M, O'Malley D, Kelly M, Golenewsky G, Martel M, et al. Extrarenal Wilms' tumor of the uterine corpus. Gynecol Oncol. 2005;96(3):892-6. eng. [PubMed ID: 15721447]. https://doi.org/10.1016/j.ygyno.2004.11.029.

  • 15.

    García-Galvis OF, Stolnicu S, Muñoz E, Aneiros-Fernández J, Alaggio R, Nogales FF. Adult extrarenal Wilms tumor of the uterus with teratoid features. Hum Pathol. 2009;40(3):418-24. [PubMed ID: 18789483]. https://doi.org/10.1016/j.humpath.2008.05.020.

  • 16.

    Comerci JJ, Denehy T, Gregori CA, Breen JL. Wilms' tumor of the uterus. A case report. J Reprod Med. 1993;38(10):829-32. eng. [PubMed ID: 8263878].

  • 17.

    Jiskoot P, Aertsens W, Degels MA, Moerman P. Extrarenal Wilms' tumor of the uterus. Eur J Gynaecol Oncol. 1999;20(3):195-7. eng. [PubMed ID: 10410884].

  • 18.

    Leblebici C, Behzatoğlu K, Yildiz P, Koçyildiz Z, Bozkurt S. Extrarenal Wilms' tumor of the uterus with ovarian dermoid cyst. Eur J Obstet Gynecol Reprod Biol. 2009;144(1):94-5. [PubMed ID: 19282087]. https://doi.org/10.1016/j.ejogrb.2008.12.021.

  • 19.

    Muc RS, Grayson W, Grobbelaar JJ. Adult extrarenal Wilms tumor occurring in the uterus. Arch Pathol Lab Med. 2001;125(8):1081-3. [PubMed ID: 11473463]. https://doi.org/10.5858/2001-125-1081-aewtoi.

  • 20.

    Pinto A, Huang M, Castillo RP, Schlumbrecht MP. Wilms Tumor of the Uterus. Int J Gynecol Pathol. 2019;38(4):335-9. [PubMed ID: 29629978]. https://doi.org/10.1097/pgp.0000000000000500.

  • 21.

    Cao M, Huang C, Wang Y, Ma D. Extrarenal Wilms' Tumor of the Female Genital System: A Case Report and Literature Review. Chin Med Sci J. 2017;32(4):274-8. https://doi.org/10.24920/J1001-9294.2017.040.

  • 22.

    Na K, Kim HS. Clinicopathologic and Molecular Characteristics of Mesonephric Adenocarcinoma Arising From the Uterine Body. Am J Surg Pathol. 2019;43(1):12-25. [PubMed ID: 29189288]. [PubMed Central ID: PMC6296843]. https://doi.org/10.1097/pas.0000000000000991.

  • 23.

    D’Hooghe E, Mifsud W, Vujanić GM. “Teratoid” Wilms tumor: the extreme end of heterologous element differentiation, not a separate entity. The American Journal of Surgical Pathology. 2019;43(11):1583-90. https://doi.org/10.1097/PAS.0000000000001335.

  • 24.

    He Y, Lu H, Zhang L. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:199-212. [PubMed ID: 30905450]. https://doi.org/10.1016/bs.pmbts.2019.01.001.

  • 25.

    Chen J, Wang J, Cao D, Yang J, Shen K, Huang H, et al. Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases. Arch Gynecol Obstet. 2021;304(4):1043-53. eng. [PubMed ID: 33751209]. [PubMed Central ID: PMC7942666]. https://doi.org/10.1007/s00404-021-06017-7.

  • 26.

    Hou W, Zhou B, Hou G, Pang Y, Sang J, Li N. Small cell neuroendocrine carcinoma expressing alpha fetoprotein in the endometrium. Open Life Sci. 2021;16(1):1219-24. [PubMed ID: 34805530]. [PubMed Central ID: PMC8580041]. https://doi.org/10.1515/biol-2021-0122.

  • 27.

    Li JJX, Lee JHS, Chan VTC, Yu MY. Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review. Case Rep Pathol. 2018;2018:3972353. [PubMed ID: 29992073]. [PubMed Central ID: PMC6016168]. https://doi.org/10.1155/2018/3972353.

  • 28.

    Sudour-Bonnange H, Coulomb-Lherminé A, Fantoni JC, Escande A, Brisse HJ, Thebaud E, et al. Standard of care for adult Wilms tumor? From adult urologist to pediatric oncologist. A retrospective review. Bull Cancer. 2021;108(2):177-86. [PubMed ID: 33129487]. https://doi.org/10.1016/j.bulcan.2020.09.007.